Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951088 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL3825684 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL3205842 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL627379 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL2159319 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL905289 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL16710011 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL12189206 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| Water SCHEMBL5203435 | 0.98 | CTSK (0.69) | CTSSCTSKALDH1A1KMT2APSENEN | |
| Water SCHEMBL10884567 | 0.98 | CTSK (0.69) | CTSSCTSKALDH1A1KMT2APSENEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115252806-A | Preparation method of nano-drug carrier G5-R with high-efficiency tumor penetration capacity | 浙江大学杭州国际科创中心 | 2022-11-01 | — | — | CN | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| CN-112480122-B | Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof | 中山大学 | 2022-03-22 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2025-04-17 | — | — | US | disclosed |
| US-RE30752-E | CHEMICAL REACTANT FOR PROTECTING AMINO OR IMINO GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-29 | — | — | US | disclosed |
| EP-0000063-B1 | DIPEPTIDE DERIVATIVES OF 7-(N-ALPHA-SUBSTITUTED OR NON-SUBSTITUTED X-ARGINYL)-AMINO-4-METHYL-COUMARIN | AJINOMOTO CO., INC. (JP) | 1981-06-10 | — | — | EP | disclosed |
| US-4215047-A | FLUOROGENIC SUBSTRATES FOR DETERMINING ENZYMATIC ACTIVITIES | AJINOMOTO COMPANY INCORPORATED (JP) | 1980-07-29 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4010178-A | Carbonic acid esters, and the preparation thereof and their use | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-03-01 | — | — | US | disclosed |
| US-3947575-A | Peptides as argiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | CTSS 2330/4885CTSK 2251/4885ALDH1A1 3188/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CTSS 138/4885CTSK 149/4885ALDH1A1 2138/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | CTSS 4052/4885CTSK 4064/4885ALDH1A1 1253/4885 |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | CTSS 4059/4885CTSK 2205/4885ALDH1A1 3140/4885 |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | CTSS 3731/4885CTSK 885/4885ALDH1A1 2003/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | CTSS 3839/4885CTSK 4188/4885ALDH1A1 1639/4885 |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | CTSS 2616/4885CTSK 1366/4885ALDH1A1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.